General Data
DataBase Content
| Peptide ID | Peptide name | Sequence | Toxicity | Hemolytic potency | Inhibitor IC50 | Unit | Target organism | Uniprot id |
| ACP1 | EK1 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.19 | µM | SARS-CoV-2 | Q8BB25 |
| ACP2 | EK1P | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.0692 | µM | SARS-CoV-2 | Q8BB25 |
| ACP3 | EK1C | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.037-0.048 | µM | SARS-CoV-2 | Q8BB25 |
| ACP4 | EK1C1 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.057 | µM | SARS-CoV-2 | Q8BB25 |
| ACP5 | EK1C2 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG | Non Toxin | 0.48 | 0.0482 | µM | SARS-CoV-2 | not found |
| ACP6 | EK1C3 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG | Non Toxin | 0.48 | 0.0106 | µM | SARS-CoV-2 | not found |
| ACP7 | EK1C4 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0025 | µM | MERS-CoV | not found |
| ACP8 | EK1C5 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0031 | µM | SARS-CoV-2 | not found |
| ACP9 | EK1C6 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0039 | µM | SARS-CoV-2 | not found |
| ACP10 | EK1C7 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0039 | µM | SARS-CoV-2 | not found |
| ACP11 | SARS-CoV-2-S(11681203) | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Non Toxin | 0.48 | >5 | µM | MERS-CoV | Q3I5J5 |
| ACP12 | MBD-4 (11-40), P9 | NGAICWGPCPTAFRQIGNCGHFKVRCCKIR | Non Toxin | 0,47 | 2.4 | µg/ml | SARS-CoV-2 | not found |
| ACP13 | SARS-CoV-S (1151-1185), SR9, SARS-CoV-2-S (1169-1203), IPB01 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Non Toxin | 0.48 | 0.022 | µM | SARS-CoV-2 | P59594 |
| ACP14 | ATN-161 | PHSCN | not determined | 0,49 | 3.16 | µM | SARS-CoV-2 | not found |
| ACP15 | AHB1 | DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR | Non Toxin | not determined | 0.035 | µM | SARS-CoV-2 | not found |
| ACP16 | AHB2 | ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK | Non Toxin | not determined | 0.0155 | µM | SARS-CoV-2 | not found |
| ACP17 | LCB1 | DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAERLLEEVER | Non Toxin | not determined | 0.00002354 | µM | SARS-CoV-2 | not found |
| ACP18 | LCB3 | NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS | Non Toxin | not determined | 0.0000481 | µM | SARS-CoV-2 | not found |
| ACP19 | MBD-4 (11-40) / P9 [H21R,K23R,K28R], P9R | NGAICWGPCPTAFRQIGNCGRFRVRCCRIR | Non Toxin | 0,46 | 0.9 | µg/ml | SARS-CoV-2 | P82019 |
| ACP20 | SARS-CoV-2-S (1169-1203)-K, IPB02 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK | Non Toxin | 0,47 | 0.025 | µM | SARS-CoV-2 | P59594 |
| ACP21 | SARS-CoV-2-S (1172-1205), IPB03 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0.48 | 0.015 | µM | SARS-CoV-2 | P59594 |
| ACP22 | SARS-CoV-2-S (1175-1205), IPB04 | SVVNIQKEIDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0.48 | 0.033 | µM | SARS-CoV-2 | P0DTC2 |
| ACP23 | SARS-CoV-2-S (1179-1205), IPB05 | IQKEIDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0.48 | >5 | µM | SARS-CoV-2 | not found |
| ACP24 | SARS-CoV-2-S (1183-1205), IPB06 | IDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0,49 | >5 | µM | SARS-CoV-2 | not found |
| ACP25 | SARS-CoV-2-S (1179-1211), IPB07 | IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK | Non Toxin | 0,47 | 0.017 | µM | SARS-CoV-2 | P59594 |
| ACP26 | SARS-CoV-2-S (1169-1198)-K, IPB08 | ISGINASVVNIQKEIDRLNEVAKNLNESLIK | Non Toxin | 0.48 | 4.66 | µM | SARS-CoV-2 | P0DTC2 |
| ACP27 | SARS-CoV-2-S (1175-1198)-K, IPB09 | SVVNIQKEIDRLNEVAKNLNESLIK | Non Toxin | 0.48 | >5 | µM | SARS-CoV-2 | P59594 |
| ACP28 | [SARS HRC-PEG4]2-chol | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGCDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC | Non Toxin | not dtermined | 0.2806 | µM | SARS-CoV-2 | not found |
| ACP29 | MERS-CoV-HR2P-GSGSGC | SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC | Non Toxin | 0,53 | >0.65 | µM | SARS-CoV-2 | not found |
| ACP30 | EK1-GSGSGC | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC | Non Toxin | 0,48 | 0.293 | µM | SARS-CoV-2 | not found |
| ACP31 | CMK | RVKR | not determined | 0,49 | 0.057 | µM | SARS-CoV-2 | not found |
| ACP32 | ACE2 (27-41) | TFLDKFNHEAEDLFYQ | Non Toxin | 0,49 | 3000 | µM | SARS-CoV-2 | Q9BYF1 |
| ACP33 | ACE2 (37-42) | EDLFYQ | not determined | 0,49 | 3000 | µM | SARS-CoV-2 | not found |
| ACP34 | Alisporivir, Debio-025 | XXXVXAAXXXX | not determined | 0,49 | 0.46 | µM | SARS-CoV-2 | not found |
| ACP1 | EK1 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.19 | µM | SARS-CoV-2 | Q8BB25 |
| ACP2 | EK1P | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.0692 | µM | SARS-CoV-2 | Q8BB25 |
| ACP3 | EK1C | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.037-0.048 | µM | SARS-CoV-2 | Q8BB25 |
| ACP4 | EK1C1 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Non Toxin | 0.48 | 0.057 | µM | SARS-CoV-2 | Q8BB25 |
| ACP5 | EK1C2 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG | Non Toxin | 0.48 | 0.0482 | µM | SARS-CoV-2 | not found |
| ACP6 | EK1C3 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSG | Non Toxin | 0.48 | 0.0106 | µM | SARS-CoV-2 | not found |
| ACP7 | EK1C4 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0025 | µM | MERS-CoV | not found |
| ACP8 | EK1C5 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0031 | µM | SARS-CoV-2 | not found |
| ACP9 | EK1C6 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0039 | µM | SARS-CoV-2 | not found |
| ACP10 | EK1C7 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSG | Non Toxin | 0.48 | 0.0039 | µM | SARS-CoV-2 | not found |
| ACP11 | SARS-CoV-2-S(11681203) | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Non Toxin | 0.48 | >5 | µM | MERS-CoV | Q3I5J5 |
| ACP12 | MBD-4 (11-40), P9 | NGAICWGPCPTAFRQIGNCGHFKVRCCKIR | Non Toxin | 0,47 | 2.4 | µg/ml | SARS-CoV-2 | not found |
| ACP13 | SARS-CoV-S (1151-1185), SR9, SARS-CoV-2-S (1169-1203), IPB01 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Non Toxin | 0.48 | 0.022 | µM | SARS-CoV-2 | P59594 |
| ACP14 | ATN-161 | PHSCN | not determined | 0,49 | 3.16 | µM | SARS-CoV-2 | not found |
| ACP15 | AHB1 | DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR | Non Toxin | not determined | 0.035 | µM | SARS-CoV-2 | not found |
| ACP16 | AHB2 | ELEEQVMHVLDQVSELAHELLHKLTGEELERAAYFNWWATEMMLELIKSDDEREIREIEEEARRILEHLEELARK | Non Toxin | not determined | 0.0155 | µM | SARS-CoV-2 | not found |
| ACP17 | LCB1 | DKEWILQKIYEIMRLLDELGHAEASMRVSDLIYEFMKKGDERLLEEAERLLEEVER | Non Toxin | not determined | 0.00002354 | µM | SARS-CoV-2 | not found |
| ACP18 | LCB3 | NDDELHMLMTDLVYEALHFAKDEEIKKRVFQLFELADKAYKNNDRQKLEKVVEELKELLERLLS | Non Toxin | not determined | 0.0000481 | µM | SARS-CoV-2 | not found |
| ACP19 | MBD-4 (11-40) / P9 [H21R,K23R,K28R], P9R | NGAICWGPCPTAFRQIGNCGRFRVRCCRIR | Non Toxin | 0,46 | 0.9 | µg/ml | SARS-CoV-2 | P82019 |
| ACP20 | SARS-CoV-2-S (1169-1203)-K, IPB02 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK | Non Toxin | 0,47 | 0.025 | µM | SARS-CoV-2 | P59594 |
| ACP21 | SARS-CoV-2-S (1172-1205), IPB03 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0.48 | 0.015 | µM | SARS-CoV-2 | P59594 |
| ACP22 | SARS-CoV-2-S (1175-1205), IPB04 | SVVNIQKEIDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0.48 | 0.033 | µM | SARS-CoV-2 | P0DTC2 |
| ACP23 | SARS-CoV-2-S (1179-1205), IPB05 | IQKEIDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0.48 | >5 | µM | SARS-CoV-2 | not found |
| ACP24 | SARS-CoV-2-S (1183-1205), IPB06 | IDRLNEVAKNLNESLIDLQELGK | Non Toxin | 0,49 | >5 | µM | SARS-CoV-2 | not found |
| ACP25 | SARS-CoV-2-S (1179-1211), IPB07 | IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK | Non Toxin | 0,47 | 0.017 | µM | SARS-CoV-2 | P59594 |
| ACP26 | SARS-CoV-2-S (1169-1198)-K, IPB08 | ISGINASVVNIQKEIDRLNEVAKNLNESLIK | Non Toxin | 0.48 | 4.66 | µM | SARS-CoV-2 | P0DTC2 |
| ACP27 | SARS-CoV-2-S (1175-1198)-K, IPB09 | SVVNIQKEIDRLNEVAKNLNESLIK | Non Toxin | 0.48 | >5 | µM | SARS-CoV-2 | P59594 |
| ACP28 | [SARS HRC-PEG4]2-chol | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGCDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC | Non Toxin | not dtermined | 0.2806 | µM | SARS-CoV-2 | not found |
| ACP29 | MERS-CoV-HR2P-GSGSGC | SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC | Non Toxin | 0,53 | >0.65 | µM | SARS-CoV-2 | not found |
| ACP30 | EK1-GSGSGC | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC | Non Toxin | 0,48 | 0.293 | µM | SARS-CoV-2 | not found |
| ACP31 | CMK | RVKR | not determined | 0,49 | 0.057 | µM | SARS-CoV-2 | not found |
| ACP32 | ACE2 (27-41) | TFLDKFNHEAEDLFYQ | Non Toxin | 0,49 | 3000 | µM | SARS-CoV-2 | Q9BYF1 |
| ACP33 | ACE2 (37-42) | EDLFYQ | not determined | 0,49 | 3000 | µM | SARS-CoV-2 | not found |
| ACP34 | Alisporivir, Debio-025 | XXXVXAAXXXX | not determined | 0,49 | 0.46 | µM | SARS-CoV-2 | not found |
Physicochemical Data
DataBase Content
| Peptide ID | Peptide name | Empiric formula | Absent amino acids | Basic residues | Acidic residues | Polar residues | Hydrophobic residues | Boman index |
| ACP1 | EK1 | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP2 | EK1P | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP3 | EK1C | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP4 | EK1C1 | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP5 | EK1C2 | C203H328N46O68S | CHPRW | 4,08 | 5 | 25,64 | 9 | 13 |
| ACP6 | EK1C3 | C203H328N46O68S | CHPRW | 4,08 | 5 | 25,64 | 9 | 13 |
| ACP7 | EK1C4 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP8 | EK1C5 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP9 | EK1C6 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP10 | EK1C7 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP11 | SARS-CoV-2-S(11681203) | C172H292N48O61 | CFHMPTWY | 3,96 | 3 | 19,44 | 9 | 15 |
| ACP12 | MBD-4 (11-40), P9 | C144H227N47O35S5 | DELMSY | 9,19 | 6 | 0 | 12 | 9 |
| ACP13 | SARS-CoV-S (1151-1185), SR9, SARS-CoV-2-S (1169-1203), IPB01 | C168H287N47O58 | CFHMPTWY | 4,1 | 3 | 17,14 | 9 | 15 |
| ACP14 | ATN-161 | C21H32N8O8S | ADEFGIKLMQRTVWY | 7,36 | 1 | 0 | 3 | 0 |
| ACP15 | AHB1 | C426H695N133O147S2 | CIPW | 4,62 | 19 | 28,24 | 8 | 25 |
| ACP16 | AHB2 | C399H633N109O128S3 | CP | 4,25 | 13 | 29,33 | 7 | 28 |
| ACP17 | LCB1 | C301H485N79O94S3 | CNPT | 4,29 | 10 | 28,57 | 6 | 20 |
| ACP18 | LCB3 | C346H556N90O106S2 | CGPW | 4,68 | 13 | 25 | 7 | 24 |
| ACP19 | MBD-4 (11-40) / P9 [H21R,K23R,K28R], P9R | C144H232N52O35S5 | DEHKLMSY | 10,51 | 6 | 0 | 12 | 9 |
| ACP20 | SARS-CoV-2-S (1169-1203)-K, IPB02 | C174H299N49O59 | CFHMPTWY | 4,39 | 4 | 16,67 | 9 | 15 |
| ACP21 | SARS-CoV-2-S (1172-1205), IPB03 | C165H283N47O56 | CFHMPTWY | 4,39 | 4 | 17,65 | 8 | 14 |
| ACP22 | SARS-CoV-2-S (1175-1205), IPB04 | C152H261N43O52 | CFHMPTWY | 4,39 | 4 | 19,35 | 7 | 12 |
| ACP23 | SARS-CoV-2-S (1179-1205), IPB05 | C135H232N38O46 | CFHMPTWY | 4,39 | 4 | 22,22 | 5 | 10 |
| ACP24 | SARS-CoV-2-S (1183-1205), IPB06 | C113H194N32O39 | CFHMPTWY | 4,26 | 3 | 21,74 | 5 | 9 |
| ACP25 | SARS-CoV-2-S (1179-1211), IPB07 | C175H288N46O57 | CFHMPTW | 4,48 | 5 | 21,21 | 7 | 11 |
| ACP26 | SARS-CoV-2-S (1169-1198)-K, IPB08 | C148H257N43O49 | CFHMPTWY | 6,65 | 4 | 12,9 | 9 | 13 |
| ACP27 | SARS-CoV-2-S (1175-1198)-K, IPB09 | C124H216N36O41 | CFGHMPTWY | 6,65 | 4 | 16 | 6 | 10 |
| ACP28 | [SARS HRC-PEG4]2-chol | C374H630N108O137S2 | FHMPTWY | 3,93 | 6 | 16,67 | 30 | 30 |
| ACP29 | MERS-CoV-HR2P-GSGSGC | C200H331N49O69S2 | FHPRW | 3,95 | 2 | 11,9 | 17 | 14 |
| ACP30 | EK1-GSGSGC | C211H341N49O72S2 | HPRW | 4,08 | 5 | 23,81 | 12 | 13 |
| ACP31 | CMK | C23H47N11O5 | ACDEFGHILMNPQSTWY | 12,52 | 3 | 0 | 0 | 1 |
| ACP32 | ACE2 (27-41) | C94H129N21O29 | CGIMPRSVW | 4,1 | 2 | 25 | 3 | 6 |
| ACP33 | ACE2 (37-42) | C38H51N7O13 | ACGHIKMNPRSTVW | 3,55 | 0 | 33,33 | 1 | 2 |
| ACP34 | Alisporivir, Debio-025 | C11H5N3O-4 | CDEFGHIKLMNPQRSTWY | 6,11 | 0 | 0 | 0 | 3 |
| ACP1 | EK1 | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP2 | EK1P | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP3 | EK1C | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP4 | EK1C1 | C196H317N43O64S | CGHPRW | 4,08 | 5 | 27,78 | 6 | 13 |
| ACP5 | EK1C2 | C203H328N46O68S | CHPRW | 4,08 | 5 | 25,64 | 9 | 13 |
| ACP6 | EK1C3 | C203H328N46O68S | CHPRW | 4,08 | 5 | 25,64 | 9 | 13 |
| ACP7 | EK1C4 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP8 | EK1C5 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP9 | EK1C6 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP10 | EK1C7 | C208H336N48O71S | CHPRW | 4,08 | 5 | 24,39 | 11 | 13 |
| ACP11 | SARS-CoV-2-S(11681203) | C172H292N48O61 | CFHMPTWY | 3,96 | 3 | 19,44 | 9 | 15 |
| ACP12 | MBD-4 (11-40), P9 | C144H227N47O35S5 | DELMSY | 9,19 | 6 | 0 | 12 | 9 |
| ACP13 | SARS-CoV-S (1151-1185), SR9, SARS-CoV-2-S (1169-1203), IPB01 | C168H287N47O58 | CFHMPTWY | 4,1 | 3 | 17,14 | 9 | 15 |
| ACP14 | ATN-161 | C21H32N8O8S | ADEFGIKLMQRTVWY | 7,36 | 1 | 0 | 3 | 0 |
| ACP15 | AHB1 | C426H695N133O147S2 | CIPW | 4,62 | 19 | 28,24 | 8 | 25 |
| ACP16 | AHB2 | C399H633N109O128S3 | CP | 4,25 | 13 | 29,33 | 7 | 28 |
| ACP17 | LCB1 | C301H485N79O94S3 | CNPT | 4,29 | 10 | 28,57 | 6 | 20 |
| ACP18 | LCB3 | C346H556N90O106S2 | CGPW | 4,68 | 13 | 25 | 7 | 24 |
| ACP19 | MBD-4 (11-40) / P9 [H21R,K23R,K28R], P9R | C144H232N52O35S5 | DEHKLMSY | 10,51 | 6 | 0 | 12 | 9 |
| ACP20 | SARS-CoV-2-S (1169-1203)-K, IPB02 | C174H299N49O59 | CFHMPTWY | 4,39 | 4 | 16,67 | 9 | 15 |
| ACP21 | SARS-CoV-2-S (1172-1205), IPB03 | C165H283N47O56 | CFHMPTWY | 4,39 | 4 | 17,65 | 8 | 14 |
| ACP22 | SARS-CoV-2-S (1175-1205), IPB04 | C152H261N43O52 | CFHMPTWY | 4,39 | 4 | 19,35 | 7 | 12 |
| ACP23 | SARS-CoV-2-S (1179-1205), IPB05 | C135H232N38O46 | CFHMPTWY | 4,39 | 4 | 22,22 | 5 | 10 |
| ACP24 | SARS-CoV-2-S (1183-1205), IPB06 | C113H194N32O39 | CFHMPTWY | 4,26 | 3 | 21,74 | 5 | 9 |
| ACP25 | SARS-CoV-2-S (1179-1211), IPB07 | C175H288N46O57 | CFHMPTW | 4,48 | 5 | 21,21 | 7 | 11 |
| ACP26 | SARS-CoV-2-S (1169-1198)-K, IPB08 | C148H257N43O49 | CFHMPTWY | 6,65 | 4 | 12,9 | 9 | 13 |
| ACP27 | SARS-CoV-2-S (1175-1198)-K, IPB09 | C124H216N36O41 | CFGHMPTWY | 6,65 | 4 | 16 | 6 | 10 |
| ACP28 | [SARS HRC-PEG4]2-chol | C374H630N108O137S2 | FHMPTWY | 3,93 | 6 | 16,67 | 30 | 30 |
| ACP29 | MERS-CoV-HR2P-GSGSGC | C200H331N49O69S2 | FHPRW | 3,95 | 2 | 11,9 | 17 | 14 |
| ACP30 | EK1-GSGSGC | C211H341N49O72S2 | HPRW | 4,08 | 5 | 23,81 | 12 | 13 |
| ACP31 | CMK | C23H47N11O5 | ACDEFGHILMNPQSTWY | 12,52 | 3 | 0 | 0 | 1 |
| ACP32 | ACE2 (27-41) | C94H129N21O29 | CGIMPRSVW | 4,1 | 2 | 25 | 3 | 6 |
| ACP33 | ACE2 (37-42) | C38H51N7O13 | ACGHIKMNPRSTVW | 3,55 | 0 | 33,33 | 1 | 2 |
| ACP34 | Alisporivir, Debio-025 | C11H5N3O-4 | CDEFGHIKLMNPQRSTWY | 6,11 | 0 | 0 | 0 | 3 |
Literature Data
DataBase Content
| Peptide ID | Peptide name | Sequence | Title | Authors | Journal | PMID |
| ACP1 | EK1 | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. | Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L | Cell Mol Immunol, 2020 | https://pubmed.ncbi.nlm.nih.gov/32047258/ |
| ACP2 | EK1P | SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL | Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. | Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L | Cell Res, 2020, 30, 343-355 | https://pubmed.ncbi.nlm.nih.gov/32231345/ |
| ACP11 | SARS-CoV-2-S(11681203) | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. | Xia S, et al. | Sci Adv, 2019, 5, eaav4580 | https://pubmed.ncbi.nlm.nih.gov/30989115/ |
| ACP12 | MBD-4 (11-40), P9 | NGAICWGPCPTAFRQIGNCGHFKVRCCKIR | A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. | Zhao H, et al. | Sci Rep, 2016, 6, 22008 | https://pubmed.ncbi.nlm.nih.gov/26911565/ |
| ACP13 | SARS-CoV-S (1151-1185), SR9, SARS-CoV-2-S (1169-1203), IPB01 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y | J Virol, 2020, 94, e00635-20 | https://pubmed.ncbi.nlm.nih.gov/32376627/ |
| ACP14 | ATN-161 | PHSCN | The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. | Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng WQ, Roy CJ, Hu TY, Kolls JK, Bix GJ | JACC Basic Transl Sci, 2021, 6, 1-8 | https://pubmed.ncbi.nlm.nih.gov/33102950/ |
| ACP15 | AHB1 | DEDLEELERLYRKAEEVAKEAKDASRRGDDERAKEQMERAMRLFDQVFELAQELQEKQTDGNRQKATHLDKAVKEAADELYQRVR | De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. | Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, Chen RE, Carter L, Walls AC, Park YJ, Strauch EM, Stewart L, Diamond MS, Veesler D, Baker D | Science, 2020, 370, 426-431 | https://pubmed.ncbi.nlm.nih.gov/32907861/ |
| ACP19 | MBD-4 (11-40) / P9 [H21R,K23R,K28R], P9R | NGAICWGPCPTAFRQIGNCGRFRVRCCRIR | A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2. | Zhao H, To KKW, Sze KH, Yung TT, Bian M, Lam H, Yeung ML, Li C, Chu H, Yuen KY | Nat Commun, 2020, 11, 4252 | https://pubmed.ncbi.nlm.nih.gov/32843628/ |
| ACP28 | [SARS HRC-PEG4]2-chol | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGCDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC | Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets | de Vries RD, Schmitz KS, Bovier FT, Noack D, Haagmans BL, Biswas S, Rockx B, Gellman SH, Alabi CA, de Swart RL, Moscona A, Porotto M | bioRxiv, 2020, doi.org/10.1101/2020.11.04.361154 | doi.org/10.1101/2020.11.04.361154 |
| ACP29 | MERS-CoV-HR2P-GSGSGC | SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGSGSGC | Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. | Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M | MBio, 2020, 11, e01935-20 | https://pubmed.ncbi.nlm.nih.gov/33082259/ |
| ACP31 | CMK | RVKR | Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. | Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, Pang YH, Lin CH, Tsai YM, Lee WH, Tao MH, Ho TC, Wu PY, Jang LT, Chen PJ, Chang SY, Yeh SH | Cell Rep, 2020, 33, 108254 | https://pubmed.ncbi.nlm.nih.gov/33007239/ |
| ACP32 | ACE2 (27-41) | TFLDKFNHEAEDLFYQ | Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. | Larue RC, Xing E, Kenney AD, Zhang Y, Tuazon JA, Li J, Yount JS, Li PK, Sharma A | Bioconjug Chem, 2021, 32, 215-223 | https://pubmed.ncbi.nlm.nih.gov/33356169/ |
| ACP34 | Alisporivir, Debio-025 | XXXVXAAXXXX | Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). | Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A | Antimicrob Agents Chemother, 2020, 64, e00876-20 | https://pubmed.ncbi.nlm.nih.gov/32376613/ |
| ASCNP1 | SARSWW-I | MWKTPTLKYFGGFNFSQI | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP2 | SARSWW-II | ATAGWTFGAGAALQIPFAMQMAY | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP3 | SARSWW-III | GYHLMSFPQAAPHGVVFLHVTW | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP4 | SARSWW-IV | GVFVFNGTSWFITQRNFFS | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP5 | SARSWW-Va | NEVAKNLNESLIDLQELGKYEQYIKWPWYVW | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP6 | SARSWW-Vb | AACEVAKNLNESLIDLQELGKYEQYIKW | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP7 | N46 | QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP8 | N46eg | QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP9 | EPL5 | KKKKYRNIRRPG | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP10 | SR9EK13 | ISGINASVVNIQEEIKKLNEEAKKLNESLIDLQEL | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP11 | SR9 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP12 | SR9EK1 | IEEINKKVEEIQKKIEELNKKAEELNKKLEELQKK | Design, synthesis and screening of antisense peptide based combinatorial peptide libraries towards an aromatic region of SARS-CoV. | Huang Y, Zhao R, Luo J, Xiong S, Shangguan D, Zhang H, Liu G, Chen Y. | J Mol Recognit. 2008 | https://pubmed.ncbi.nlm.nih.gov/18383098/ |
| ASCNP13 | peptide 9626 | TLKPIFKLPLGINITNFR | Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. | Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. | J Virol. 2008 | https://jvi.asm.org/content/82/1/588 |
| ASCNP14 | HR2 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. | Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. | J Virol. 2008 | https://jvi.asm.org/content/82/1/589 |
| ASCNP15 | HR1-a | YENQKQIANQFNKAISQIQESLTTTSTA | Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. | Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. | J Virol. 2008 | https://jvi.asm.org/content/82/1/590 |
| ASCNP16 | GST-removed HR2 | DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI | Identification of a new region of SARS-CoV S protein critical for viral entry. | Guo Y, Tisoncik J, McReynolds S, Farzan M, Prabhakar BS, Gallagher T, Rong L, Caffrey M. | J Mol Biol. 2009 | https://pubmed.ncbi.nlm.nih.gov/19853613/ |
| ASCNP17 | HR1-b | IQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSS | Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. | Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. | J Cell Biochem. 2008 | https://pubmed.ncbi.nlm.nih.gov/18442051/ |
| ASCNP18 | His6-HR1 | YENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSV | Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. | Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. | J Cell Biochem. 2008 | https://pubmed.ncbi.nlm.nih.gov/18442051/ |
| ASCNP19 | K10 | DLKGKYVQIP | Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. | Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. | J Cell Biochem. 2008 | https://pubmed.ncbi.nlm.nih.gov/18442051/ |
| ASCNP2 | SARSWW-II | ATAGWTFGAGAALQIPFAMQMAY | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP3 | SARSWW-III | GYHLMSFPQAAPHGVVFLHVTW | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP4 | SARSWW-IV | GVFVFNGTSWFITQRNFFS | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP5 | SARSWW-Va | NEVAKNLNESLIDLQELGKYEQYIKWPWYVW | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP6 | SARSWW-Vb | AACEVAKNLNESLIDLQELGKYEQYIKW | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. | Sainz B Jr, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, Garry RF. | Virus Res. 2006 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP7 | N46 | QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP8 | N46eg | QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP9 | EPL5 | KKKKYRNIRRPG | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP10 | SR9EK13 | ISGINASVVNIQEEIKKLNEEAKKLNESLIDLQEL | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP11 | SR9 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. | Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK. | Antiviral Res. 2009 | https://pubmed.ncbi.nlm.nih.gov/18983873/ |
| ASCNP12 | SR9EK1 | IEEINKKVEEIQKKIEELNKKAEELNKKLEELQKK | Design, synthesis and screening of antisense peptide based combinatorial peptide libraries towards an aromatic region of SARS-CoV. | Huang Y, Zhao R, Luo J, Xiong S, Shangguan D, Zhang H, Liu G, Chen Y. | J Mol Recognit. 2008 | https://pubmed.ncbi.nlm.nih.gov/18383098/ |
| ASCNP13 | peptide 9626 | TLKPIFKLPLGINITNFR | Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. | Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. | J Virol. 2008 | https://jvi.asm.org/content/82/1/588 |
| ASCNP14 | HR2 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. | Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. | J Virol. 2008 | https://jvi.asm.org/content/82/1/589 |
| ASCNP15 | HR1-a | YENQKQIANQFNKAISQIQESLTTTSTA | Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. | Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. | J Virol. 2008 | https://jvi.asm.org/content/82/1/590 |
| ASCNP16 | GST-removed HR2 | DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI | Identification of a new region of SARS-CoV S protein critical for viral entry. | Guo Y, Tisoncik J, McReynolds S, Farzan M, Prabhakar BS, Gallagher T, Rong L, Caffrey M. | J Mol Biol. 2009 | https://pubmed.ncbi.nlm.nih.gov/19853613/ |
| ASCNP17 | HR1-b | IQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSS | Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. | Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. | J Cell Biochem. 2008 | https://pubmed.ncbi.nlm.nih.gov/18442051/ |
| ASCNP18 | His6-HR1 | YENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSV | Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. | Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. | J Cell Biochem. 2008 | https://pubmed.ncbi.nlm.nih.gov/18442051/ |
| ASCNP19 | K10 | DLKGKYVQIP | Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. | Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM. | J Cell Biochem. 2008 | https://pubmed.ncbi.nlm.nih.gov/18442051/ |
| ASCNP20 | K20 | NCVKMLCTHTGTGQAITVTP | Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2-O-methyltransferase activity of nsp10/nsp16 complex. | Ke M, Chen Y, Wu A, Sun Y, Su C, Wu H, Jin X, Tao J, Wang Y, Ma X, Pan JA, Guo D. | Virus Res. 2012 | https://pubmed.ncbi.nlm.nih.gov/22659295/ |
| ASCNP21 | K8 | PTTCANDP | Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2-O-methyltransferase activity of nsp10/nsp16 complex. | Ke M, Chen Y, Wu A, Sun Y, Su C, Wu H, Jin X, Tao J, Wang Y, Ma X, Pan JA, Guo D. | Virus Res. 2012 | https://pubmed.ncbi.nlm.nih.gov/22659295/ |
| ASCNP22 | P9 | CANLLLQYGSFCTQLNRALSGIA | Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2-O-methyltransferase activity of nsp10/nsp16 complex. | Ke M, Chen Y, Wu A, Sun Y, Su C, Wu H, Jin X, Tao J, Wang Y, Ma X, Pan JA, Guo D. | Virus Res. 2012 | https://pubmed.ncbi.nlm.nih.gov/22659295/ |
| ASCNP23 | P8 | PSSKRFQPFQQFGRDVSDFT | Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2-O-methyltransferase activity of nsp10/nsp16 complex. | Ke M, Chen Y, Wu A, Sun Y, Su C, Wu H, Jin X, Tao J, Wang Y, Ma X, Pan JA, Guo D. | Virus Res. 2012 | https://pubmed.ncbi.nlm.nih.gov/22659295/ |
| ASCNP24 | P10 | RNTREVFAQVKQMYKTPTLKYFG | Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2-O-methyltransferase activity of nsp10/nsp16 complex. | Ke M, Chen Y, Wu A, Sun Y, Su C, Wu H, Jin X, Tao J, Wang Y, Ma X, Pan JA, Guo D. | Virus Res. 2012 | https://pubmed.ncbi.nlm.nih.gov/22659295/ |
| ASCNP25 | P6 | TKFPSVYAWERKKISNCVAD | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP26 | P5 | KGIYQTSNFRVVPSGDVVRF | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP27 | P2 | KSNVVRGWVFGSTMNNKSQS | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP28 | P4 | TDAVDCSQNPLAELKCSVKSF | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP29 | P1 | TSSMRGVYYPDEIFRSDTLYL | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP30 | P3 | YKGYQPIDVVRDLPSGFNTL | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP31 | P7 | YNYKYRYLRHGKLRPFERDI | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP32 | HR2-1 | VYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVV | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP33 | HR2-2 | QPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQ | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP34 | HR2-3 | SFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNE | Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. | Lu W, Wu XD, Shi MD, Yang RF, He YY, Bian C, Shi TL, Yang S, Zhu XL, Jiang WH, Li YX, Yan LC, Ji YY, Lin Y, Lin GM, Tian L, Wang J, Wang HX, Xie YH, Pei G, Wu JR, Sun B. | FEBS Lett. 2005 | https://pubmed.ncbi.nlm.nih.gov/15811330/ |
| ASCNP35 | HR2-4 | LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAK | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP36 | HR2-5 | FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP37 | HR2-6 | PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQ | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP38 | HR2-7 | GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP39 | HR2-8 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP40 | HR2-9 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP41 | HR2-10 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP42 | HR2-11 | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP43 | HR2-12 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP44 | HR2-13 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP45 | HR2-14 | INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP46 | HR2-15 | INASVVNIQKEIDRLNEVAKNLNESLIDL | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP47 | HR2-16 | VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP48 | HR2-17 | VVNIQKEIDRLNEVAKNLNESLIDLQELGK | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP49 | HR2-19 | IQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP50 | HR2-20 | IDRLNEVAKNLNESLIDLQELGKYEQYIKWPW | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP51 | sHR2-1 | LDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP52 | sHR2-2 | PKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP53 | sHR2-3 | LDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP54 | sHR2-4 | FKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP55 | sHR2-5 | TSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP56 | sHR2-6 | VDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP57 | sHR2-7 | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP58 | sHR2-8 | ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP59 | sHR2-9 | ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP60 | sHR2-10 | ELDSPKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLID | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP61 | mHR2 | DLSLDFEKLNVTLLDLTYEMNRIQDAIKKLNESYINLKE | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP62 | sHR1 | AYRFNGIQVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP63 | sHR1c | NQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP64 | NP-1 | GVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQ | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP65 | NP-2 | LTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFG | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP66 | NP-3 | KQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITG | Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, Rottier PJ. | Proc Natl Acad Sci U S A. 2004 | https://pubmed.ncbi.nlm.nih.gov/15184046/ |
| ASCNP67 | NP-4 | GRLQSLQTYVTQQLIRAAEIRASANLAATKMSEC | Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. | Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. | Lancet. 2004 | https://pubmed.ncbi.nlm.nih.gov/15043961/ |
| ASCNP68 | CP-1 | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. | Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. | Lancet. 2004 | https://pubmed.ncbi.nlm.nih.gov/15043961/ |
| ASCNP69 | CP-2 | KEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVW | Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. | Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. | Lancet. 2004 | https://pubmed.ncbi.nlm.nih.gov/15043961/ |
| ASCNP70 | Mucroporin | LFGLIPSLIGGLVSAFK | Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. | Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. | Lancet. 2004 | https://pubmed.ncbi.nlm.nih.gov/15043961/ |
| ASCNP71 | Mucroporin-M1 | LFRLIKSLIKRLVSAFK | Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. | Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. | Lancet. 2004 | https://pubmed.ncbi.nlm.nih.gov/15043961/ |
| ASCNP72 | Mucroporin-S1 | SLIGGLVSAFK | Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. | Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S. | Lancet. 2004 | https://pubmed.ncbi.nlm.nih.gov/15043961/ |
| ASCNP73 | Mucroporin-S2 | VSAFK | Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. | Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, Yang J, Zhang Y, Shi W, Cao Z, Wu Y, Yan H, Li W. | Peptides. 2011 | https://pubmed.ncbi.nlm.nih.gov/21620914/ |
| ASCNP74 | SEQ ID NO:1 | FKLPLGINITNFRAILTAFS | Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. | Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, Yang J, Zhang Y, Shi W, Cao Z, Wu Y, Yan H, Li W. | Peptides. 2011 | https://pubmed.ncbi.nlm.nih.gov/21620914/ |
| ASCNP75 | SEQ ID NO:2 | PTTFMLKYDENGTITDAVDC | Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. | Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, Yang J, Zhang Y, Shi W, Cao Z, Wu Y, Yan H, Li W. | Peptides. 2011 | https://pubmed.ncbi.nlm.nih.gov/21620914/ |
| ASCNP76 | SEQ ID NO:3 | VLYNSTFFSTFKCYGVSATK | Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. | Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, Yang J, Zhang Y, Shi W, Cao Z, Wu Y, Yan H, Li W. | Peptides. 2011 | https://pubmed.ncbi.nlm.nih.gov/21620914/ |
| ASCNP77 | SEQ ID NO:4 | PALNCYWPLNDYGFYTTSGI | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61522 |
| ASCNP78 | SEQ ID NO:5 | RDVSDFTDSVRDPKTSEILD | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61523 |
| ASCNP79 | SEQ ID NO:6 | YQDVNCTDVSTAIHADQLTP | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61524 |
| ASCNP80 | SEQ ID NO:7 | SNNTIAIPTNFSISITTEVM | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61525 |
| ASCNP81 | SEQ ID NO:8 | QYGSFCTQLNRALSGIAAEQ | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61526 |
| ASCNP82 | SEQ ID NO:9 | GIGVTQNVLYENQKQIANQF | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61527 |
| ASCNP83 | SEQ ID NO:10 | IQKEIDRLNEVAKNLNESLI | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61528 |
| ASCNP84 | MHVWW-IV | GYFVQDDGEWKFTGSSYYY | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61529 |
| ASCNP85 | HR2L | SIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNY | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61530 |
| ASCNP86 | HR2P | SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof | Bojian, Yi, Jiandong, Ming-Liang | The University of Hong Knog, (CN) | https://hub.hku.hk/handle/10722/61531 |
| ASCNP87 | HR2P-M1 | SLTQINTTLLDLEYEMRSLQQVVKALNESYIDLKEL | Inhibition of severe acute respiratory syndrome-associated coronavirus(SARS-CoV) infectivity by peptides analogous to the viral spike protein | Sainz B, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, et al | VirusRes 2006;120(1-2):146–55 | https://pubmed.ncbi.nlm.nih.gov/16616792/ |
| ASCNP88 | HR2P-M2 | SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL | Structure-based discovery ofMiddle East Respiratory Syndrome Coronavirus fusion inhibitor. | Sainz B, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, et al | VirusRes 2006;120(1-2):146–56 | https://pubmed.ncbi.nlm.nih.gov/24473083/ |
| ASCNP89 | H | HVTTTFAPPPPR | Structure-based discovery ofMiddle East Respiratory Syndrome Coronavirus fusion inhibitor. | Sainz B, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, et al | VirusRes 2006;120(1-2):146–57 | https://pubmed.ncbi.nlm.nih.gov/24473083/ |
| ASCNP90 | S | SVVPSKATWGFA | Structure-based discovery ofMiddle East Respiratory Syndrome Coronavirus fusion inhibitor. | Sainz B, Mossel EC, Gallaher WR, Wimley WC, Peters CJ, Wilson RB, et al | VirusRes 2006;120(1-2):146–58 | https://pubmed.ncbi.nlm.nih.gov/24473083/ |
| ASCNP91 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Protec-tive effect of intranasal regimens containing peptidic Middle East RespiratorySyndrome Coronavirus fusion inhibitor against MERS-CoV Infection | Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, et al | J InfectDis 2015;212(12):1894–903. | https://pubmed.ncbi.nlm.nih.gov/26164863/ |
| ASCNP92 | Urumin | IPLRGAFINGRWDSQCHRFSNGAIACA | Phage displayed peptides recognizing porcineaminopeptidase N inhibit transmissible gastroenteritis coronavirus infectionin vitro | Ren X, Liu B, Yin J, Zhang H, Li G | Virology 2011;410(2):299–306 | https://pubmed.ncbi.nlm.nih.gov/21176936/ |
| ASCNP93 | NYAD | ITFXDLLXYYGP | Phage displayed peptides recognizing porcineaminopeptidase N inhibit transmissible gastroenteritis coronavirus infectionin vitro | Ren X, Liu B, Yin J, Zhang H, Li G | Virology 2011;410(2):299–307 | https://pubmed.ncbi.nlm.nih.gov/21176936/ |
| ASCNP94 | G1 | LRSRTKIIRIRH | The catalytic subunit of the SWR1 remodeler is a histone chaperone for the H2A.Z-H2B dimer | Hong J, et al. (2014) | Mol Cell 53(3):498-505 | https://www.yeastgenome.org/reference/S000156974 |
| ASCNP95 | G2 | MPRRRRIRRRQK | An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses | David J Holthausen 1, Song Hee Lee 1, Vineeth Tv Kumar 2, Nicole M Bouvier 3, Florian Krammer 3, Ali H Ellebedy 1, Jens Wrammert 1, Anice C Lowen 1, Sanil George 2, Madhavan Radhakrishna Pillai 2, Joshy Jacob | Immunity 2017 Apr 18;46(4):587-595. | https://pubmed.ncbi.nlm.nih.gov/28423338/ |
| ASCNP96 | Latarcin 1 | SMWSGMWRRKLKKLRNALKKKLKGE | Spn1 regulates the recruitment of Spt6 and the Swi/Snf complex during transcriptional activation by RNA polymerase II | Zhang L, et al. (2008) | Mol Cell Biol 28(4):1393-403 | https://www.yeastgenome.org/reference/S000125985 |
| ASCNP97 | Epinecidin 1 | GFIFHIIKGLFHAGKMIHGLV | PHYTOCHEMICAL CONSTITUENTS AND ANTIMICROBIAL ACTIVITIES OF THE ROOT BARK EXTRACTS OF Massularia acuminata spp | U. S. Ukekpe1,2,*, H. M. Adamu2 , E.O. Ekanem2 and A. A. Saleh3 | International Journal of Advanced Research (IJAR) | http://www.journalijar.com/article/5741/phytochemical-constituents-and-antimicrobial-activities-of-the-root-bark-extracts-of-massularia-acuminata-spp./ |
| ASCNP98 | Cecropin A | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | PHYTOCHEMICAL CONSTITUENTS AND ANTIMICROBIAL ACTIVITIES OF THE ROOT BARK EXTRACTS OF Massularia acuminata spp | U. S. Ukekpe1,2,*, H. M. Adamu2 , E.O. Ekanem2 and A. A. Saleh4 | International Journal of Advanced Research (IJAR) | http://www.journalijar.com/article/5741/phytochemical-constituents-and-antimicrobial-activities-of-the-root-bark-extracts-of-massularia-acuminata-spp./ |
| ASCNP99 | HBD-2, 3 | LKKLCKLLKKLCKLAG | Identification of crucial yeast inhibitors in bio-ethanol and improvement of fermentation at high pH and high total solids | Huang H, et al. (2011) | Bioresour Technol | https://www.yeastgenome.org/reference/S000145571 |
| ASCNP100 | Hp1036 | ILGKIWEGIKSIF | Virocidal activity of Egyptian scorpion venoms against hepatitis C virus Hepatitis viruses | Alaa M H El-Bitar 1 2, Moustafa M H Sarhan 3, Chie Aoki 4, Yusuke Takahara 5, Mari Komoto 6, Lin Deng 7, Mohsen A Moustafa 8, Hak Hotta 9 | Virology Journal | https://pubmed.ncbi.nlm.nih.gov/25889296/ |
| ASCNP101 | Hp1239 | ILSYLWNGIKSIF | Virocidal activity of Egyptian scorpion venoms against hepatitis C virus Hepatitis viruses | Alaa M H El-Bitar 1 2, Moustafa M H Sarhan 3, Chie Aoki 4, Yusuke Takahara 5, Mari Komoto 6, Lin Deng 7, Mohsen A Moustafa 8, Hak Hotta 9 | Virology Journal | https://pubmed.ncbi.nlm.nih.gov/25889296/ |
| ASCNP102 | Indolicidin | ILPWKWPWWPWRR | Sources of plastic marine debris on beaches of Korea: More from the ocean than the land | Yong Chang Jang, Jongmyoung Lee, Sunwook Hong, Jong Su Lee, Won Joon Shim & Young Kyoung Song | Ocean Science Journal | https://link.springer.com/article/10.1007/s12601-014-0015-8 |
| ASCNP103 | caerin 1.10 | GLLSVLGSVAKHVLPHVVPVIAEKL | The catalytic subunit of the SWR1 remodeler is a histone chaperone for the H2A.Z-H2B dimer | Hong J, et al | Mol Cell | https://www.yeastgenome.org/reference/S000156975 |
| ASCNP104 | caerin 1.6 | GLFSVLGAVAKHVLPHVVPVIAEKL | Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration | T E Robinson 1, K E Browman, H S Crombag, A Badiani | Neurosci Biobehav Rev | https://pubmed.ncbi.nlm.nih.gov/9579324/ |